Item 7.01 Regulation FD Disclosure.

On Dec 28, 2022, Oncotelic Therapeutics, Inc. (the "Company"), issued a letter to its shareholders from its Chief Executive Officer, Dr. Vuong Trieu.

? JV continues to advance to its IPO

? OT-101 immunotherapy expanding with at least 10 planned IIS clinical trials for

2023

? OT-101 commercialization effort expanding on multiple fronts

? Manufacturing and DAO capabilities being built with platform launched slated


   for 2023




Disclaimer.

The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Forward-Looking Statements.

This Current Report on Form 8-K may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, (i) statements with respect to the Company's plans, objectives, expectations and intentions; and (ii) other statements identified by words such as "may", "could", "would", should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. Forward-looking statements in this document include, without limitation, statements regarding the Company's expectations regarding the expectation and timing of AL-101's approval through its proposed 505(b)(2) applications, whether the Company will complete development of AL-101, and the anticipated use of proceeds therefrom. These statements are based upon the current beliefs and expectations of the Company's management and may be subject to significant risks and uncertainties; and that no assurances can be given that such expectations shall be fulfilled.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits.



                                                            Incorporation by
Exhibit No.   Description                                   reference

99.1            Press Release                               Filed herewith
104           Cover Page Interactive Data File (embedded
              within the Inline XBRL document)




-2-

© Edgar Online, source Glimpses